10201-73-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4-methoxypyridine is used as a pharmaceutical agent for its ability to selectively inhibit iNOS. This property makes it a potential candidate for the development of drugs targeting conditions where iNOS overexpression or dysregulation is implicated, such as inflammatory diseases, autoimmune disorders, and certain types of cancer.
Used in Research Applications:
In the field of scientific research, 2-Amino-4-methoxypyridine serves as a valuable tool for studying the role of nitric oxide (NO) in various biological processes. As a selective iNOS inhibitor, it can help researchers understand the specific contributions of iNOS-derived NO to cellular signaling, immune responses, and other physiological functions.
Used in Drug Development:
2-Amino-4-methoxypyridine is utilized in the development of novel therapeutics that aim to modulate the activity of iNOS. By inhibiting this enzyme, these drugs may offer potential benefits in treating conditions associated with excessive NO production, such as chronic inflammation, neurodegenerative diseases, and cardiovascular disorders.
Overall, 2-Amino-4-methoxypyridine's unique chemical properties and its role as a selective iNOS inhibitor make it a versatile compound with applications in the pharmaceutical industry, research, and drug development.

Synthesis Reference(s)

The Journal of Organic Chemistry, 72, p. 4554, 2007 DOI: 10.1021/jo070189y

InChI:InChI=1/C6H8N2O/c1-9-5-2-3-8-6(7)4-5/h2-4H,1H3,(H2,7,8)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 124-41-4 sodium methylate 
• 74404-98-1 2,2-dimethyl-3-(4-methoxypyrid-2-yl)-4-oxo-4H-1,3-benzoxazine 
• 551950-46-0 tert-butyl N-(4-methoxypyridin-2-yl)carbamate 
• 90151-10-3 4-methoxypyridine-2-carboxamide 
• 187973-18-8 4-methoxy-pyridine-2-carboxylic acid hydrazide 
• 5470-22-4 4-chloropicolinic acid 
• 67-56-1 methanol 
• 5123-13-7 5,5-dimethyl-2-phenyl-1,3,2-dioxaborinane 
• 89488-29-9 2-bromo-4-methoxypyridine 
• 98-98-6 2-Picolinic acid 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 130721-78-7 tert-butyl (4-chloropyridin-2-yl) carbamate 
• 29681-43-4 methyl 4-methoxypicolinate 

Downstream Products

• 128615-98-5 2-[(E)-2-(3-Benzyloxy-4-nitro-phenyl)-vinyl]-7-methoxy-3-methyl-imidazo[1,2-a]pyridine 
• 328062-49-3 3-acetyl-6-methoxy-2-methylimidazo[1,2-a]pyridine 
• 117348-06-8 {2-[1-(4-Methoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine 
• 84487-08-1 4-methoxy-3-nitro-pyridin-2-ylamine 
• 854515-82-5 ethyl 7-methoxy-2-methylimidazo[1,2-a]pyridine-3-carboxylate 
• 1204527-87-6 C₉H₁₀N₂O 
• 1204429-09-3 8-methoxy-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one 
• 342613-71-2 7-methoxy-imidazo[1,2-a]pyridine 
• 896722-39-7 7-methoxy-imidazo[1,2-a]pyridine-3-carbaldehyde 
• 896722-40-0 C₁₈H₂₀N₂O₅ 
• 1313547-54-4 N-(4-methoxypyridin-2-yl)-4-nitrobenzenesulfonamide 
• 88617-87-2 4-amino-N-(4-methoxy-pyridin-2-yl)-benzenesulfonamide 
• 1232431-11-6 5-bromo-4-methoxy-pyridin-2-ylamine 
• 1374233-54-1 C₁₇H₁₄BrFN₂O₃ 

Relevant academic research and scientific papers

Tetracarbonylmolybdenum complexes of 2-(phenylazo) pyridine ligands. Correlations of molybdenum-95 chemical shifts with electronic, infrared, and electrochemical properties

The complexes cis-Mo(CO)4(X-2-(phenylazo)pyridine) (X = 4-CH3O, 4-CH3, H, 4-Cl, 5-Br, 5-CF3, 6-CH3) and cis-Mo(CO)4(2-(2-CH3-phenylazo)pyridine) have been synthesized and characterized by cyclic voltammetry, by visible and infrared spectroscopy, and by 1H, 13C, and 95Mo NMR spectroscopy. The 95Mo chemical shift correlates with the lowest energy electronic transition, with the sum of the carbonyl stretching frequencies, with the first oxidation potential, and with Hammett σ parameters for the pyridyl substituents. The failure of the complexes cis-Mo(CO)4(6-CH3-2-(phenylazo)pyridine) and cis-Mo(CO)4(2-(2-CH3-phenylazo)pyridine) to fit some of the correlations is attributed to steric or electronic effects. The effect of a substituent on the pyridyl ring of 2-(phenylazo)pyridine appears to be entirely an inductive one operating through the σ bonding. It is suggested that the 2-(phenylazo)pyridines might be appropriately viewed as ligands whose strong π-acceptor ability resides with the azo group, while the pyridyl group acts primarily as a pyridine whose basicity has been decreased by the strong electron-withdrawing 2-phenylazo substituent.

A convenient synthetic route to substituted pyrrolo[2,3-b]pyridines via a novel ethylene-bridged compound

A convenient synthetic route to 4-substituted pyrrolo[2,3-b]pyridines is presented. The novel ethylene bridged compound 1,2-bis(4-azidopyrrolo[2,3-b]pyridinyl)ethene was prepared and further derivatized. The novel synthesis was applied in the preparation of 3-cyano-4-hydroxypyrrolo[2,3-b]pyridine.

Ruthenium-Catalyzed Reductive Arylation of N-(2-Pyridinyl)amides with Isopropanol and Arylboronate Esters

A new three-component reductive arylation of amides with stable reactants (iPrOH and arylboronate esters), making use of a 2-pyridinyl (Py) directing group, is described. The N-Py-amide substrates are readily prepared from carboxylic acids and PyNH2, and the resulting N-Py-1-arylalkanamine reaction products are easily transformed into the corresponding chlorides by substitution of the HN-Py group with HCl. The 1-aryl-1-chloroalkane products allow substitution and cross-coupling reactions. Therefore, a general protocol for the transformation of carboxylic acids into a variety of functionalities is obtained. The Py-NH2 by-product can be recycled.

BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME

Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain amino-pyridine-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R3, R4, R5, R6, and the subscript n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

Consecutive gold(I)-catalyzed cyclization reactions of o -(buta-1,3-diyn-1-yl-)-substituted N-aryl ureas: A one-pot synthesis of pyrimido[1,6- a ]indol-1(2 H)-ones and related systems

Treatment of readily available o-(buta-1,3-diyn-1-yl-)-substituted N-aryl ureas such as 1 with the Au(I)-catalyst 11 affords, via a twofold cyclization process, the isomeric pyrimido[1,6-a]indol-1(2H)-one 3 in good yield.

Synthesis of C8-N9 annulated purines by iron-catalyzed C-H amination

Purine and simple: A short synthesis for substituted annulated purine derivatives based on an Fe-catalyzed direct amination reaction using oxygen as oxidant was developed (see scheme). Interestingly, iron proved to be superior to copper catalysis. Copyright

Ligandless copper-catalyzed coupling of heteroaryl bromides with gaseous ammonia

A range of different N- and S-containing heterocyclic bromides can be efficiently coupled with gaseous ammonia in the presence of copper(II) acetylacetonate [Cu(acac)2] as catalyst and in the absence of additional ligands. Unstable aminothiophenes and aminobenzothiophenes can be further reacted in situ to afford functionalized derivatives. Copyright

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF

The compounds according to formula (I), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modula